MoneyWorks4Me

Cadila Healthcare informs about press release

13 Sep 2018 Evaluate

Cadila Healthcare has informed about press release titled, 'Zydus receives final approval from the USFDA for Risedronate Sodium Delayed-Release Tablets'.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1109.15 0.35 (0.03%)
21-Aug-2026 10:58 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1893.40
Dr. Reddys Labs. 1177.35
Cipla 1427.30
Lupin 2197.60
Zydus Lifesciences 1109.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: